BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CASI Pharmaceuticals\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies CASI Pharmaceuticals\, Inc.'s dru
 gs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07946549-3186@assetmemo.bio
DTSTAMP:20261121T005935Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:CID-103: Phase 2 readout est. (NCT07946549)
DESCRIPTION:CID-103\, phase 2\, Immune Thrombocytopenia.\nStudy: A Study to
  Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune
  Thrombocytopenia\nEstimated primary completion: 30 November 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cid-103#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07946549
URL:https://assetmemo.bio/drug/cid-103#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07641426-3186@assetmemo.bio
DTSTAMP:20261121T005935Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:CID-103: Phase 1/2 readout est. (NCT07641426)
DESCRIPTION:CID-103\, phase 1/2.\nStudy: A Two Part Dose-escalation Safety 
 and Efficacy Study of CID-103 in Adults With Active and Chronic Active Ren
 al Allograft Antibody Mediated Rejection (ABMR).\nEstimated primary comple
 tion: May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cid-1
 03#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7641426
URL:https://assetmemo.bio/drug/cid-103#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
